BioSpace News Archive

Polyphor announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its novel immuno-oncology candidate balixafortide (POL6326), in combination with eribulin, for the treatment of patients with HER2-negative metastatic breast cancer who previously received at least two chemotherapeutic regimens in the metastatic setting.

Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) announced today they have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological diseases

Varian (NYSE: VAR) today announced it has received FDA 510(k) clearance for its Calypso® Anchored Beacon® transponder.

Real-world data analysis shows extended half-life coagulation factor products bring high cost

2017 Net Sales of Inavir® in Japan Exceeded ¥20 Billion, Triggering USD $5 Million Milestone Payment

The Chan Zuckerberg Initiative, a donor-advised fund of Silicon Valley Community Foundation, is funding 85 projects, including three at UC Santa Cruz, to support efforts to develop a comprehensive reference atlas of all cells in the human body

electroCore, a commercial-stage bioelectronic medicine company, will be presenting data from the PRESTO study evaluating gammaCore for the acute treatment of migraine.

Epigenomics AG announced promising results from two clinical studies published in EBioMedicine supported by Cell Press and The Lancet, demonstrating high accuracy of Epigenomics’ proprietary epigenetic circulating biomarker mSEPT9 in detecting liver cancer among patients with cirrhosis.

BONE THERAPEUTICS will announce its full year results for the year ended 31 December 2017 on Wednesday 25 April 2018 at 7am CEST.

Catalyst Pharmaceuticals, Inc. announced that the first patient has been enrolled into its Phase 3 clinical trial (designated as MSK-002) to evaluate the efficacy and safety of Firdapse® (amifampridine phosphate) in patients with MuSK antibody positive Myasthenia Gravis (MuSK-MG).